Management ChangeMay 7, 2026, 07:08 PM
Cue Biopharma Appoints Shao-Lee Lin as CEO; Grants Inducement Equity
AI Summary
Cue Biopharma announced the appointment of Shao-Lee Lin, M.D., Ph.D., as its new President and Chief Executive Officer. The company granted inducement equity awards to Dr. Lin and six other new employees on May 3, 2026. These awards, made under the 2026 Inducement Stock Incentive Plan, were approved by independent directors as a material inducement for their employment.
Key Highlights
- Shao-Lee Lin appointed President and CEO of Cue Biopharma.
- Dr. Lin received options to purchase 655,074 shares at $30.42 per share.
- Dr. Lin received 327,537 restricted stock units, fully vested upon grant.
- Six other new employees received options for 518,599 shares at $30.42 per share.
- Six other new employees received 327,534 restricted stock units, fully vested upon grant.
- Awards granted under the Company’s 2026 Inducement Stock Incentive Plan.